Bexsero Study is a Phase II, randomized, observer-blind, placebo-controlled, multi-site trial of the FDA licensed rMenB+OMVNZ vaccine, Bexsero. The primary objective of the study is to demonstrate efficacy of Bexsero in prevention of urogenital and/or anorectal gonococcal infection. The targeted study population is men and women 18-50 years of age who are disproportionately vulnerable to N.gonorrhoeae infection. Approximately 2,200 participants globally are expected to be enrolled. The study site managed by SEARCH is at the Chulalongkorn Faculty of Medicine in Bangkok, Thailand. The site is expected to enroll 500 participants and more than 50% have already been enrolled in 2022.